ReShape Lifesciences Inc.
RSLS
$0.365
-$0.015-3.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -7.74% | -16.55% | -23.00% | -24.82% | -22.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.74% | -16.55% | -23.00% | -24.82% | -22.79% |
| Cost of Revenue | -5.78% | -42.16% | -39.56% | -33.49% | -29.47% |
| Gross Profit | -8.85% | 5.16% | -11.28% | -19.37% | -18.44% |
| SG&A Expenses | -44.49% | -45.96% | -47.33% | -47.13% | -39.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.07% | -42.04% | -42.67% | -41.95% | -35.80% |
| Operating Income | 54.45% | 55.94% | 53.09% | 50.36% | 41.63% |
| Income Before Tax | 37.45% | 73.27% | 74.56% | 73.60% | 75.67% |
| Income Tax Expenses | -23.08% | 288.57% | 115.71% | 113.13% | 113.68% |
| Earnings from Continuing Operations | 37.38% | 72.98% | 74.09% | 73.21% | 75.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.38% | 72.98% | 74.09% | 73.21% | 75.36% |
| EBIT | 54.45% | 55.94% | 53.09% | 50.36% | 41.63% |
| EBITDA | 54.12% | 54.39% | 50.54% | 46.98% | 36.82% |
| EPS Basic | 93.29% | 91.23% | 51.00% | -47.73% | -- |
| Normalized Basic EPS | 92.44% | 90.26% | 59.06% | -34.34% | -- |
| EPS Diluted | 93.29% | 91.23% | 51.00% | -47.73% | -- |
| Normalized Diluted EPS | 92.44% | 90.26% | 59.06% | -34.34% | -- |
| Average Basic Shares Outstanding | 402.22% | 1,012.90% | 1,261.75% | 2,562.37% | -- |
| Average Diluted Shares Outstanding | 402.22% | 1,012.90% | 1,261.75% | 2,562.37% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |